| Patent Number |
Title Of Patent |
Date Issued |
| 6174900 |
Substituted piperidine derivative for treating urinary disturbance |
January 16, 2001 |
| Disclosed herein is a substituted piperidine derivative represented by the following general formula (1): ##STR1##wherein R.sup.1 means an aryl or heteroaryl group which may have at least one substituent, R.sup.2 denotes an alkyl, alkenyl or aralkyl group, R.sup.3 stands for a hydrog |
| 6171520 |
Reagents for labeling SH groups, process for the preparation of them and method for labeling wit |
January 9, 2001 |
| Disclosed are SH-labeling reagents containing acridine compounds represented by the following formula (I): ##STR1##whereinA represents the following group:orin which Q represents a group --S.sup.+ RX.sup.- --, a group --N.sup.+ RR.sub.1 X.sup.- -- wherein R.sub.1 represents an alkyl grou |
| 6103538 |
Colloidal gold immunoassay method |
August 15, 2000 |
| Disclosed herein is a method for the detection of a target substance by a colloidal gold immunoassay, which comprises dissolving in an immunoreaction system a metal salt selected from the group consisting of sodium, potassium and lithium fluorides, sodium, potassium, lithium and magn |
| 6063945 |
Triazole derivative or salt thereof |
May 16, 2000 |
| A compound having formula (2): ##STR1## wherein R represents hydrogen, a straight or branched C.sub.1-10 alkyl group, a C.sub.7-11 aralkyl group or a C.sub.2-10 carboacyl group and m stands for 1 to 5. |
| 6046218 |
Pyridine derivative and medicament containing the same as an effective ingredient |
April 4, 2000 |
| Described is a pyridine derivative represented by the following formula (1): ##STR1## wherein R.sup.1 and R.sup.2 individually represent H, an alkyl group, a cycloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group which may have a substituent, a carboxyalkyl group, an alkoxy |
| 6002028 |
Triazole derivative, preparation process thereof and pharmaceutical comprising the same as an ef |
December 14, 1999 |
| Described is a triazole derivative represented by the formula (1) or salt thereof, preparation process thereof, preparation intermediates represented by the formulas (2) and (3), and a pharmaceutical comprising the compound represented by the formula (1) or salt thereof. ##STR1## |
| 5986144 |
Triazole derivative, preparation process thereof and pharmaceutical comprising the same as an ef |
November 16, 1999 |
| Described is a triazole derivative represented by the formula (1) or salt thereof, preparation process thereof, preparation intermediates represented by the formulas (2) and (3), and a pharmaceutical comprising the compound represented by the formula (1) or salt thereof. wherein n st |
| 5968956 |
Substituted piperidine derivative and medicine comprising the same |
October 19, 1999 |
| Disclosed herein is a substituted piperidine derivative represented by the following general formula (1): ##STR1## wherein R.sup.1 means an aryl or heteroaryl group which may have at least one substituent, R.sup.2 denotes an alkyl, alkenyl or aralkyl group, R.sup.3 stands for a h |
| 5945438 |
Triazole derivative and pharmaceutical comprising the same as an effective ingredient |
August 31, 1999 |
| Described is a triazole derivative represented by the formula (1) or salt thereof, preparation process thereof, preparation intermediates represented by the formulas (2) and (3), and a pharmaceutical comprising the compound represented by the formula (1) or salt thereof. ##STR1## |
| 5939448 |
Triazole derivative or salt thereof |
August 17, 1999 |
| Described is a triazole derivative represented by the formula (1): wherein R represents a hydrogen atom, an alkyl group, an aralkyl group or an acyl group, n stands for 0 to 2 and m stands for 1 to 5 or salt thereof, and a pharmaceutical containing the derivative or salt as an effective |
| 5935977 |
Substituted vinyl pyridine derivative and drugs containing the same |
August 10, 1999 |
| The present invention relates to a substituted vinylpyridine derivative represented by the following formula (1): ##STR1## (wherein R.sup.1 represents a hydrogen atom, an alkyl group, etc., R.sup.2 represents an alkyl group; one of R.sup.3 and R.sup.4, which are different from ea |
| 5922767 |
Substituted benzylurea derivatives and medicine containing the same |
July 13, 1999 |
| Disclosed herein are substituted benzylurea derivatives represented by the following general formula (1): ##STR1## wherein R.sup.1 and R.sup.2 are independently H, a halogen atom, or an alkyl or alkoxyl group, R.sup.3 is a phenyl or heterocyclic group which may be substituted, n |
| 5902826 |
Platinum (IV) complex and pharmaceutical composition comprising the same |
May 11, 1999 |
| A diamine-platinum (IV) complex represented by the following formula (1): ##STR1## wherein R.sup.1 and R.sup.2 together represent R.sup.5 O--CH(CH.sub.2 NH.sub.2).sub.2 (R.sup.5 represents hydrogen, acetyl, trifluoroacetyl, benzoyl, cycloalkylcarbonyl or methanesulfonyl) or a C.sub.5 |
| 5866609 |
Substituted vinylurea derivatives and medicine containing the same |
February 2, 1999 |
| Disclosed herein are substituted vinylurea derivatives represented by the following general formula (1): ##STR1## wherein R.sup.1 and R.sup.3 are independently a phenyl group which may be substituted, R.sup.2 is a phenyl group which may be substituted, or a cycloalkyl group, and |
| 5789419 |
4-quinolinone derivative or salt thereof |
August 4, 1998 |
| This invention relates to a 4-quinolinone derivative represented by the following general formula (1): ##STR1## wherein R.sup.1 and R.sup.2 mean individually H, halogen, cyano, or lower alkyl, lower alkylsulfonyl, lower alkylsulfinyl, lower alkylthio or lower alkoxy which may be |
| 5710152 |
Benzoazine derivative or salt thereof and pharmaceutical compostion comprising the same |
January 20, 1998 |
| A benzoazine derivative represented by the following formula (1), ##STR1## wherein R.sup.1 represents an alkyl group, alkoxy group, halogen atom, halogenoalkyl group, amino group, hydroxy group, benzyloxy group which may have a substituent, cyano group, carbamoyl group, acyl group, n |
| 5707878 |
Method for detecting blood component using conidiobolus hemagglutinin |
January 13, 1998 |
| A method for detecting blood component in a sample comprising reacting a human erythrocyte membrane band 3 glycoprotein (band 3) in the sample and a hemagglutinin produced by a microorganism belonging to the genus Conidiobolus (CA) and measuring said band 3 glycoprotein contained in a |
| 5676970 |
Anti-inflammatory analgesic plaster |
October 14, 1997 |
| An anti-inflammatory analgesic plaster carries thereon a base which comprises piroxicam and a polyoxyethylene nonionic surfactant having 5-15 moles of added ethylene oxide. |
| 5654002 |
Piroxicam tablets and production and process thereof |
August 5, 1997 |
| A process is provided for the production of piroxicam tablets. According to the process, a solution of a water-soluble high-molecular substance is added to a mixture of piroxicam and lactose. The resultant mixture is granulated and then compressed into tablets. |
| 5585511 |
Platinum complex and malignant tumor treating drug containing the same |
December 17, 1996 |
| A platinum complex represented by the following formula (1): ##STR1## wherein the all symbols are defined in the disclosure; and a malignant tumor treating drug which contains the complex as an active ingredient. The platinum complex is excellent in antitumor effects and safety and i |
| 5578600 |
Stable liquid preparation of complex vitamin for internal use |
November 26, 1996 |
| Described is a stable liquid preparation of complex vitamin for internal use. The preparation containing vitamin B.sub.1 and vitamin B.sub.12, and as a sweetening agent, a sugar alcohol. The pH of the preparation has been adjusted to 3.5 to 4.5. |
| 5532371 |
Piperazine substituted carboxylic acid derivatives for treating hyperlipimia |
July 2, 1996 |
| An arylamide derivative of formula (1), a salt thereof and a therapeutic agent for hyperlipemia which comprises the derivative or salt: ##STR1## wherein Ar represents a group ##STR2## a naphthyl group, a pyridinyl group, a furyl group, a thienyl group, a quinolyl group or an |
| 5500221 |
Sustained release suppository |
March 19, 1996 |
| The present invention relates to a sustained-release suppository preparation characterized by comprising an acidic drug or a salt thereof which can be absorbed by rectal administration and an acidic compound or a pH buffering agent. The sustained-release suppository preparation of the |
| 5498780 |
Platinum complex and malignant tumor treating drug containing the same |
March 12, 1996 |
| A diamine-platinum complex represented by the following formula (1): ##STR1## wherein the all definitions are defined in the disclosure, and a malignant tumor treating drug which contains the above complex as an active ingredient. The diamine-platinum complex has a high water solubil |
| 5496819 |
Antiphlogistic-analgesic plaster comprising triacetin and piroxicam |
March 5, 1996 |
| An antiphlogistic-analgesic plaster comprising piroxicam and triacetin and/or triethyl citrate.The antiphlogistic-analgesic plaster of the invention is excellent in percutaneous absorption of piroxicam and hence has an excellent antiphlogistic and analgesic effect. |
| 5496561 |
Controlled release-initiation and controlled release-rate pharmaceutical composition |
March 5, 1996 |
| A controlled release-initiation and controlled release-rate pharmaceutical composition in which a drug-containing composition is coated with a membrane layer comprising a water insoluble high polymer and silicone. The starting time for the release of drugs from the controlled release |
| 5447926 |
Quinolone carboxylic acid derivatives |
September 5, 1995 |
| A quinolone carboxylic acid derivative having the following formula (1), ##STR1## wherein R.sup.1 is a hydrogen atom, an alkyl group, an aralkyl group, an ester residual group which can be hydrolyzed in living bodies, R.sup.2 is a hydrogen atom or an amino group which may be substitu |
| 5440036 |
1,4-benzoxazine derivatives |
August 8, 1995 |
| A 1,4-benzoxazine derivative represented by the following formula (1): ##STR1## wherein R.sup.1 represents an unsubstituted or halogen-substituted lower alkyl, unsubstituted or halogen-substituted lower alkylsulfonyl, nitro or cyano group, R.sup.2 and R.sup.3 may be the same or diffe |
| 5430028 |
5-aminoquinolone carboxylic acid derivative and antibacterial agent containing the same as activ |
July 4, 1995 |
| A 5-aminoquinolone carboxylic acid derivative represented by the following general formula (1): ##STR1## wherein R.sup.1 means a hydrogen atom, an amino group, a linear or branched alkyl group having 1-5 carbon atoms and an alkylamino group containing a linear or branched alkyl g |
| 5422102 |
Antiinflammatory and analgesic gel preparation |
June 6, 1995 |
| An antiinflammatory and analgesic gel preparation comprising diclofenac or its salts, an ester of dibasic acid, a lower alcohol, and a nonionic polymer or a mixture of nonionic polymers selected from the group consisting of (a) 1.5-4% by weight of hydroxypropyl cellulose having a mol |
| 5411972 |
Arylamide derivatives for treating hyperlipemia |
May 2, 1995 |
| An arylamide derivative of formula (1), a salt thereof and a therapeutic agent for hyperlipemia which comprises the derivative or salt: ##STR1## wherein Ar represents a group ##STR2## a naphthyl group, a pyridinyl group, a furyl group, a thienyl group, a quinolyl group or an |
| 5405840 |
Pranoprofen-containing, suspending medicinal composition |
April 11, 1995 |
| A pranoprofen-containing, suspending medicinal composition is formed of the following three ingredients (a) to (c):(a) pranoprofen;(b) a suspending agent comprising microcrystalline cellulose-sodium carboxymethylcellulose, sodium carboxymethylcellulose and hydroxypropyl methylcellulose; |
| 5385900 |
Quinoline carboxylic acid derivatives |
January 31, 1995 |
| A quinolone carboxylic acid derivative having the following formula (1), ##STR1## wherein R.sup.1 is a hydrogen atom, an alkyl group, an aralkyl group, an ester residual group which can be hydrolyzed in living bodies, R.sup.2 is a hydrogen atom or an amino group which may be substitu |
| 5350769 |
Antiinflammatory gel preparation |
September 27, 1994 |
| The present invention relates to an antiinflammatory gel preparation comprising an ammonium or sodium salt of diclofenac, a nonionic polymer, a dibasic ester, and a lower alcohol. The gel preparation of the present invention exhibits superior percutaneous absorptivity, thus providing |
| 5348744 |
Antidiarrheal compositions containing loperamide hydrochloride and a saccharide |
September 20, 1994 |
| Described herein are antidiarrheal compositions containing loperamide hydrochloride as an effective ingredient and a saccharide, for example, a monosaccharide, oligosaccharide or sugar alcohol in an amount as much as at least 3,000 times the weight of loperamide hydrochloride. |
| 5324735 |
Quinoline carboxylic acid derivatives |
June 28, 1994 |
| The present invention relates to a quinolone carboxylic acid derivative represented by the following the formula (I), ##STR1## wherein R.sub.1 is a lower alkyl group, R.sub.2 is a hydrogen atom or a lower alkyl group, R.sub.3 is a hydrogen atom or a halogen atom, R.sub.4 and R.su |
| 5300517 |
Piperidine compounds having anti-acetylcholinesterase activity |
April 5, 1994 |
| Piperidine compounds of formula II: ##STR1## that exhibit anticholinesterase activity and are effective in treating dementia. |
| 5275825 |
Compressed-molded preparations |
January 4, 1994 |
| Compressed molded preparations are disclosed. In the preparation coated granules of a pharmaceutical composition are compressed and molded together with non-coated component(s) containing 10% or more by weight of non-swelling polymers. According to the preparation there is little bre |
| 5258375 |
Composition for the preparation of dosage-form active vitamins D.sub.3 containing polyvinylaceta |
November 2, 1993 |
| Compositions suitable for use in the preparation of dosage-form active vitamins D.sub.3 are disclosed. Each composition comprises an active vitamin D.sub.3 and a stabilizer selected from polyvinylacetal diethylaminoacetate and hydroxypropylcellulose. Also disclosed are processes for |
| 5240934 |
Quinoline derivatives |
August 31, 1993 |
| Quinoline derivatives of the formula, ##STR1## wherein >A represents a group >N--(CH.sub.2).sub.n --, >C.dbd., >C.dbd.CH(CH.sub.2).sub.n --, or >CH(CH.sub.2).sub.n --, wherein n is an integer of 0-7; Y represents a group >C.dbd.O or >CHOH, R.sup.1 is a hydrog |
| 5231101 |
Benzo[5,6]cyclohepta[1,2-B]pyridine derivatives and antiallergic agents comprising same |
July 27, 1993 |
| Benzo[5,6]cyclohepta[1,2-b]pyridine derivatives of the following formula: ##STR1## wherein R.sup.1 represents a cyano, carbamoyl, alkylsulfoxy, alkylsulfonyl, tetrazolyl or sulfonic acid group, and R.sup.2 represents a hydrogen atom, a cyano, phenyl, aralkyl, alkoxycarbonylalkyl, |
| 5225206 |
Sustained-release pranoprofen preparation |
July 6, 1993 |
| A sustained-release pranoprofen preparation is disclosed. The preparation comprises an effective amount of pranoprofen and one or more sustained-release components selected from the group consisting of oily components, water-soluble components, water-insoluble components, and intesti |
| 5208035 |
Diclofenac sodium plaster |
May 4, 1993 |
| A diclofenac sodium plaster has a backing material and a paste spread on the backing material. The paste is composed of diclofenac sodium, a penetration enhancer composed of 1-menthol and propylene glycol, and a hydrophilic base composed principally of a water-soluble polymer. |
| 5204087 |
Composition for foaming preparation |
April 20, 1993 |
| A composition for foaming preparation comprising (a) an organic acid of which the crystal surface is coated with a sugar and (b) a carbonate is disclosed. In the composition, an organic acid is completely shut off from a carbonate by a sugar coating so that the acid does not react with t |
| 5190951 |
Quinoline derivatives |
March 2, 1993 |
| Quinoline derivatives of the formula, ##STR1## wherein > A represents a group >N--(CH.sub.2).sub.n --, >C.dbd., >C.dbd.CH(CH.sub.2).sub.n --, or >CH(CH.sub.2).sub.n --, wherein n is an integer of 0-7; Y represents a group >C.dbd.O or >CHOH, R.sup.1 is a hydro |
| 5186943 |
Compressed-molded preparations |
February 16, 1993 |
| Compressed-molded preparations are disclosed. In the preparation coated granules of a pharmaceutical composition are compressed and molded together with non-coated component(s) containing 10% or more by weight of non-swelling polymers. According to the preparation there is little bre |
| 5182112 |
Antidiarrheal compositions containing laperamide hydrochloride and a saccharide |
January 26, 1993 |
| Described herein are antidirarrheal compositions containing loperamide hydrochloride as an effective ingredient and a saccharide, for example, a monosaccharide, oligosaccharide or sugar alcohol in an amount as much as at least 3,000 times the weight of loperamide hydrochloride. |
| 5164513 |
Imidazole derivative |
November 17, 1992 |
| Novel imidazole derivatives and their acid adducts are disclosed. The imidazole derivatives are represented by formula: ##STR1## wherein R.sub.1 represents an alkyl group, R.sub.2 represents a hydrogen atom, an alkyl group which may have a substituent, or an aralkyl group which m |
| 5164193 |
Sustained-release tablet |
November 17, 1992 |
| A sustained-release tablet is disclosed. The tablet is a combination of powder (A) comprising an oil component, water insoluble polymer, or both, and a pharmaceutically active component and powder (B) comprising a water soluble polymer and a pharmaceutically active component. An ideal re |
| 5159091 |
Process for preparing 21-desoxyprednisolone 17-esters |
October 27, 1992 |
| A process for preparing 21-desoxyprednisolone 17-esters of formula (IV) is disclosed. ##STR1## The process comprises reacting a prednisolone 17.alpha.,21-cyclic orthoester with an acid in a 40-60% lower alcohol solution to produce a prednisolone 17-ester, sulfonylating the predni |
